BDBM107710 US11426393, Compound Table XV.16::US8598210, Table XV, 16::US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hydroxypyridine-2-carbonyl]amino}-acetic acid::US9598370, Example 00141::USRE47437, Example {[5-(2-Methyl-5-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-aceticacid

SMILES Cc1ccc(Cl)cc1-c1cnc(C(=O)NCC(O)=O)c(O)c1

InChI Key InChIKey=XFZFCHHQSHMUBB-UHFFFAOYSA-N

Data  5 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 107710   

TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataEC50:  3.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataEC50:  3.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataEC50:  3.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataIC50:  2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US11426393, Compound Table XV.16 | US8598210, Tabl...)
Affinity DataEC50:  3.30E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent